Table 1.

The FDA Drug Label for Pegloticase. Glucose-6-phosphate dehydrogenase Deficiency Associated Hemolysis and Methemoglobinemia (2020)

PhenotypeRecommendations
G6PD deficiencyScreen individuals at risk for G6PD deficiency before starting pegloticase. For example, individuals of African, Mediterranean (including Southern European and Middle Eastern), and Southern Asian ancestry are at increased risk for G6PD deficiency.
Life threatening hemolytic reactions and methemoglobinemia have been reported with pegloticase in individuals with G6PD deficiency. Because of the risk of hemolysis and methemoglobinemia, do not administer pegloticase to individuals with G6PD deficiency.

This table is adapted from (1).

From: Pegloticase Therapy and G6PD Genotype

Cover of Medical Genetics Summaries
Medical Genetics Summaries [Internet].
Pratt VM, Scott SA, Pirmohamed M, et al., editors.
Copyright Notice

All Medical Genetics Summaries content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which permits copying, distribution, and adaptation of the work, provided the original work is properly cited and any changes from the original work are properly indicated. Any altered, transformed, or adapted form of the work may only be distributed under the same or similar license to this one.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.